3Sonic Raises €1.3M Seed to Advance AI-Supported 3D Ultrasound for Cancer Surgery

3Sonic Secures €1.3M Seed Funding

3Sonic, a Danish medtech spin-out from the SURGiC research group at Rigshospitalet and the Technical University of Denmark (DTU), has raised €1.3 million in seed funding. The round included participation from BioInnovation Institute.

What 3Sonic Does

3Sonic is developing an AI-supported 3D ultrasound imaging platform for cancer surgery. The portable, sensorless system scans resected tumor specimens directly in the operating room and generates high-resolution 3D images in under ten minutes. This allows surgeons to verify margins in real time instead of waiting on pathology.

Clinical proof of concept has been completed with oral cancer patients using a fully functional prototype. The company is now maturing the technology toward broader clinical use.

Funding Details

• Round: Seed
• Amount: €1,300,000 EUR
• Date: September 8, 2026
• Investors: BioInnovation Institute

Why This Matters for Acquisitions

The medtech and surgical imaging space continues to see innovation aimed at improving intraoperative decision-making. 3Sonic's technology addresses a key challenge in cancer surgery: the need for rapid, accurate margin assessment. By providing real-time 3D imaging in the operating room, the platform could reduce the need for follow-up surgeries and improve patient outcomes.

With this seed funding, 3Sonic is positioned to further develop its technology and move toward broader clinical adoption. This could make it an attractive acquisition target for larger medical device companies or healthcare technology firms looking to enhance their surgical imaging portfolios.

About the Investor

BioInnovation Institute participated in the round. The institute supports early-stage life science companies and innovations.

Looking Ahead

3Sonic plans to use the funding to mature its technology and expand clinical validation. The successful proof of concept in oral cancer patients provides a foundation for further development and potential regulatory approvals. As the company progresses, it may seek additional funding to support clinical trials and commercialization efforts.